Dr. Cochran highlighted the advantages of the TULSA Procedure, stating that its unique MRI guidance and thermography allow for the treatment of a broader range of prostate conditions with an improved safety profile. The transition from a private pay model to a Medicare model has resulted in a remarkable 500% increase in the number of TULSA Procedures performed, demonstrating the growing demand and acceptance of this cutting-edge therapy.
Arun Menawat, CEO and Chairman of Profound Medical, expressed his congratulations to Dr. Cochran and his team for this achievement, emphasizing the importance of the TULSA Procedure in enhancing patient care and outcomes. The TULSA Procedure is performed using the TULSA-PRO® system, which allows for precise, incision-free therapy tailored to individual patient needs, minimizing side effects typically associated with traditional surgical methods.
Profound Medical continues to innovate in the field of interventional MRI procedures, aiming to expand access to personalized, non-invasive treatment options for patients worldwide. The company's technologies are approved across major global markets, including the United States, Europe, Canada, and Australia, further solidifying its position as a leader in the medical device industry.
